Researchers reported that adenine base editing (ABE) can rescue a cryptic splice mutation tied to cardiac-type Fabry disease in cells. The work, published in Gene Therapy, targets a specific G>A mutation at the IVS4+919 site, aiming to restore correct splicing rather than cutting DNA. The study adds to the case for splice-aware base editing as a strategy for conditions where the pathogenic driver is subtle—changes that disrupt transcript processing rather than producing a straightforward protein-coding swap. From a biotech pipeline perspective, the update reinforces how precision editing approaches are moving beyond proof-of-concept toward clinically relevant mutation classes, including splice defects in inherited metabolic and lysosomal disorders.